- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- OncNursingNews.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
San Antonio Breast Cancer Symposium | Conferences
Safety of T-DM1/Temozolomide for The Prevention of HER2-Breast Cancer Associated Brain Mets
December 11, 2021
Alexandra S. Zimmer, MD, discusses the safety of the combination of the T-DM1 ado-trastuzumab emtansine and temozolomide, for the prevention of further brain metastases in patients with HER2-positive breast cancer with brain metastases.
Pathologic CR After Neoadjuvant Therapy Equally Likely in Black and White Women With Breast Cancer
December 10, 2021
In the phase 2 I-SPY 2 platform trial, receipt of targeted neoadjuvant chemotherapy did not appear to be based on race.
Resolution of Fatigue and GI Toxicity Possible After Olaparib Treatment in BRCA+ High-Risk eBC
December 10, 2021
Adverse events in patients with high-risk HER2-negative early breast cancer treated with chemotherapy before olaparib may be resolved after therapy is complete.
Utility of T-DM1 in Patients With HER2-Positive Breast Cancer
December 10, 2021
Alexandra Higgins, MD, discusses when to use ado-trastuzumab emtansine in patients with HER2-positive breast cancer, and how to address particular adverse events that patients may develop while on treatment.
Samuraciclib/Fulvestrant Combo Shows Activity in HR+ Breast Cancer
December 10, 2021
Samuraciclib plus fulvestrant demonstrates activity in patients with HR-positive breast cancer who were heavily pretreated with CDK4/6 inhibitors.
Likelihood of Relapse in TNBC Can be Identified With Early Use of ctDNA Testing
December 09, 2021
Circulating tumor DNA should be used early and often by physcians who treat patients with early-stage triple-negative breast cancer.
T-DXd as Second-Line Standard in HER2+ Metastatic Breast Cancer Supported by Subgroup Analysis
December 09, 2021
Fam-trastuzumab deruxtecan-nxki led to prolonged progression-free survival and higher responses compared with ado-trastuzumab emtansine as second-line therapy in patients with HER2-positive metastatic breast cancer.
Palbociclib Treatment Supported for Black and Hispanic Patients With HR+, HER2- Beast Cancer
December 09, 2021
Data from a pooled analysis confirm that patients who self-identify as Black or Hispanic can safely benefit from treatment with palbociclib plus endocrine therapy for hormone receptor–positive, HER2-negative advanced breast cancer.
CNS-PFS Prolonged With Tucatinib Plus Palbociclib/Letrozole in HR+/HER2+ Breast Cancer
December 08, 2021
A non-chemotherapy–based targeted regimen comprised of tucatinib, palbociclib, and letrozole was found to prolong central nervous system (CNS) progression-free survival (PFS) in patients with hormone receptor–positive, HER2-positive breast cancer.
Premenopausal ER+ Breast Cancer Recurrence Reduced Significantly With Aromatase Inhibitors
December 08, 2021
Compared with tamoxifen, aromatase inhibitors were revealed to be more effective in reducing the rate of recurrence in ER+ breast cancer among premenopausal women receiving ovarian suppression.